News

Latest News:

mc2_news-image-icon-05

EPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary

POSTED: November 9, 2021

Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once- daily topical treatment of plaque psoriasis in adults 18 years of age or older


CHARLESTON, SC, USA and ...

READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021

POSTED: September 29, 2021

  • Poster # P1447: A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment ...

    READ FULL ARTICLE >

mc2_news-image-icon-05

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to WYNZORA® Cream for treatment of Plaque Psoriasis

POSTED: February 17, 2021

In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

Upcoming Events:

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >

© mc2 therapeutics 2020